Exelixis Q1 revenue rises to $610.8 million; board authorizes new $750 million buyback
Exelixis reported first-quarter 2026 total revenues of $610.8 million, up from $555.4 million a year earlier, and GAAP diluted EPS of $0.79, up from $0.55. The company maintained its 2026 financial guidance and said the zanzalintinib NDA for previously treated metastatic colorectal cancer is under FDA review with a December 3, 2026 target action date. The Board also authorized up to an additional $750 million in stock repurchases through December 31, 2027.
Key points
- Total revenues were $610.8 million versus $555.4 million; net product revenues were $555.0 million versus $513.3 million.
- GAAP diluted EPS was $0.79 versus $0.55; non-GAAP diluted EPS was $0.87 versus $0.62.
- 2026 guidance was maintained, with total revenues of $2.525 billion to $2.625 billion.
- The new $750 million repurchase program runs through December 31, 2027; the October 2025 program is expected to be completed in May 2026.
The filing
Written by AI on Nov 8, 2026, 1:11 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.